

## AbstractID: 8849 Title: When the Oxygen Level Matters mostly during Radiation Therapy of Cervical Cancer?

**Purpose:** To investigate, at what time point in therapy the patient hemoglobin (Hgb) levels and the blood perfusion in cervical cancer have the greatest impact on outcome prediction of radiation/chemotherapy (RT/CT).

**Method and Materials:** Eighty-eight patients with cervical cancer stages IB2-IVA were treated with standard RT/CT. Serial weekly blood tests, including Hgb levels, were collected and all patients underwent 4 serial DCE-MRI: pre-RT, at 2-2.5 weeks, at 4-5 weeks during RT and 1-2 months post-RT. Mean follow-up was 4.7 (range 0.1-9.0) years. Hgb level, representing systemic oxygenation, and the lowest 10<sup>th</sup> percentile of signal intensity within tumor (SI10), representing local tumor blood supply, were combined and evaluated for various time points to predict the effectiveness of RT/CT. Outcome analyses were carried out with Mann-Whitney rank-sum test and Kaplan-Meier method.

**Results:** In separate analyses, the best time for outcome prediction for either Hgb or SI10 was at 2-2.5 weeks into treatment and a dose of 20-25 Gy. The p-value for local tumor control was <0.001 and 0.013 for Hgb<sub>2wk</sub> and SI10<sub>2wk</sub> respectively, significantly better than at the other time points, ranging 0.02-0.4 for Hgb and 0.06-0.95 for SI10. Low tumor oxygenation, reflected by simultaneously low Hgb and low SI10, significantly correlated with local tumor recurrence. The 5-year local recurrence rates are 45% vs. 7% at 2-2.5 weeks (p<0.001) respectively, compared to 36% vs. 9% at pre-therapy (p=0.003), and 37% vs. 9% at 4-5 weeks (p=0.003).

**Conclusion:** Combining information of patient Hgb levels and tumor perfusion provides a good indirect measure of the tumor oxygenation in cervical cancer. This study indicated that examinations performed early in therapy at a dose of 20-25 Gy, significantly correlated with therapy outcome, and could be used to identify early those patients at risk of local tumor recurrence.

**Conflict of Interest (only if applicable):** N/A